PRESS RELEASE : MorphoSys and Incyte Announce -2-

lymphoma, the further clinical development of tafasitamab-cxix, including ongoing confirmatory trials, additional 
interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional 
approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi. The words "anticipate," "believe," 
"estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" 
and similar expressions are intended to identify forward-looking statements, although not all forward-looking 
statements contain these identifying words. The forward-looking statements contained herein represent the judgment of 
MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the 
actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be 
materially different from any historic or future results, financial conditions and liquidity, performance or 
achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, 
performance, financial condition and liquidity, and the development of the industry in which it operates are consistent 
with such forward-looking statements, they may not be predictive of results or developments in future periods. Among 
the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the 
impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, 
including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical 
supply of current or future drug candidates, commercial supply of current or future approved products, and launching, 
marketing and selling current or future approved products, the global collaboration and license agreement for 
tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' 
ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, 
additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible 
additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi, MorphoSys' reliance on 
collaborations with third parties, estimating the commercial potential of its development programs and other risks 
indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. 
Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on 
such forward-looking statements. These forward-looking statements speak only as of the date of publication of this 
document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document 
to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on 
which any such statement is based or that may affect the likelihood that actual results will differ from those set 
forth in the forward-looking statements, unless specifically required by law or regulation. 
Incyte Forward-Looking Statements 
Except for the historical information set forth herein, the matters set forth in this press release, including 
statements regarding Incyte's ongoing clinical development program for tafasitamab in patients with relapsed/refractory 
follicular lymphoma (FL) or marginal zone lymphoma (MZL), the enrollment, design, and timing and results of the 
clinical trial program, including the inMIND study, and whether tafasitamab will become an approved treatment option 
for patients with relapsed or refractory FL or relapsed or refractory MZL, contain predictions, estimates and other 
forward-looking statements. 
These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that 
may cause actual results to differ materially, including unanticipated developments in and risks related to: 
unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful 
or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll 
sufficient numbers of subjects in clinical trials; determinations made by the FDA; Incyte's dependence on its 
relationships with its collaboration partners; the efficacy or safety of Incyte's products and the products of the 
Incyte's collaboration partners; the acceptance of Incyte's products and the products of Incyte's collaboration 
partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater 
than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to 
time in Incyte's reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended 
December 31, 2020. Incyte disclaims any intent or obligation to update these forward-looking statements. 
For more information, please contact: 
MorphoSys 
Media contacts:                    Investor contacts: 
Thomas Biegi                       Dr. Julia Neugebauer 
Vice President                     Senior Director 
Tel.: +49 (0)89 / 89927 26079      Tel: +49 (0)89 / 899 27 179 
[e-mail]         [e-mail] 
Jeanette Bressi                    Myles Clouston 
Director, US Communications        Senior Director 
Tel: [phone]               Tel: [phone] 
[e-mail]      [e-mail] 
 
Incyte 
Media contacts:                    Investor contact: 
Catalina Loveman                   Christine Chiou 
Executive Director, Public Affairs Senior Director, Investor Relations 
Tel: [phone]               Tel: [phone] 
[e-mail]                [e-mail] 
 
Jenifer Antonacci 
Senior Director, Public Affairs 
Tel: [phone] 
[e-mail] 

References^[1] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375-2390.

^[2] Decision Resources Group. Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, Landscape & Forecast. 2020. -----------------------------------------------------------------------------------------------------------------------

2021-04-19 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      MorphoSys AG 
              Semmelweisstr. 7 
              82152 Planegg 
              Germany 
Phone:        [phone] 
Fax:          [phone] 
E-mail:       [e-mail] 
Internet:     www.morphosys.com 
ISIN:         DE0006632003 
WKN:          663200 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq 
EQS News ID:  1186257 
 
End of News   DGAP News Service 
=------------ 

1186257 2021-04-19

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1186257&application_name=news

(END) Dow Jones Newswires

April 19, 2021 16:01 ET (20:01 GMT)